Cargando…

Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy

BACKGROUND: Tumour expression of selected microRNAs (miRs) correlates with cisplatin efficacy in multiple cancers. We investigated the role of selected miRs in patients receiving cisplatin-based therapy for advanced urothelial carcinoma (UC). METHODS: RNA was extracted from formalin-fixed paraffin-e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bellmunt, Joaquim, Zhou, Chensheng Willa, Mullane, Stephanie A, Werner, Lillian, Taplin, Mary-Ellen, Fay, André P, Choueiri, Toni K, Orsola, Anna, Takeda, David Y, Hahn, William C, Kim, Jaegil, Sonpavde, Guru, Bowden, Michaela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931368/ https://www.ncbi.nlm.nih.gov/pubmed/27351382 http://dx.doi.org/10.1038/bjc.2016.146

Ejemplares similares

Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors
por: Bellmunt, Joaquim, et al.
Publicado: (2015)

Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma
por: Mullane, Stephanie A., et al.
Publicado: (2016)

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)
por: Rosenberg, Jonathan E., et al.
Publicado: (2018)

The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine
por: Harshman, L C, et al.
Publicado: (2013)

Transcriptomic analysis of micropapillary high grade T1 urothelial bladder cancer
por: Bowden, Michaela, et al.
Publicado: (2020)

Identification of ALK Gene Alterations in Urothelial Carcinoma
por: Bellmunt, Joaquim, et al.
Publicado: (2014)

HER2 as a target in invasive urothelial carcinoma
por: Bellmunt, Joaquim, et al.
Publicado: (2015)

A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma
por: Nassar, Amin H., et al.
Publicado: (2019)

Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma
por: Hoffman-Censits, Jean, et al.
Publicado: (2020)

FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma
por: Adib, Elio, et al.
Publicado: (2021)

Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors
por: Nuzzo, Pier Vitale, et al.
Publicado: (2020)

Precision Medicine to Treat Urothelial Carcinoma—The Way Forward
por: Luceno, Carvy Floyd, et al.
Publicado: (2023)

Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma
por: Bellmunt, Joaquim, et al.
Publicado: (2018)

Urothelial carcinoma management in elderly or unfit patients()
por: Bellmunt, Joaquim, et al.
Publicado: (2016)

Obesity and Outcomes in Patients with Metastatic Urothelial Carcinoma(1)
por: Leiter, Amanda, et al.
Publicado: (2016)

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer
por: Zhang, Tian, et al.
Publicado: (2020)

FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder
por: Guancial, Elizabeth A, et al.
Publicado: (2014)

Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes
por: Grivas, Petros, et al.
Publicado: (2018)

Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma
por: Nassar, Amin H., et al.
Publicado: (2019)

Prognostic impact of tumor infiltrating lymphocytes on patients with metastatic urothelial carcinoma receiving platinum based chemotherapy
por: Huang, Hui-Shan, et al.
Publicado: (2018)

Upper tract urothelial carcinoma: a different disease entity in terms of management
por: Leow, Jeffrey J, et al.
Publicado: (2017)

Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma
por: Sonpavde, G, et al.
Publicado: (2012)

Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study
por: Di Lorenzo, Giuseppe, et al.
Publicado: (2015)

Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials
por: Moreira, Raphael B., et al.
Publicado: (2017)

Circulating Biomarkers in Bladder Cancer
por: Nandagopal, Lakshminarayanan, et al.
Publicado: (2016)

Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer
por: Gourdin, Theodore, et al.
Publicado: (2018)

Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer
por: Thomas, Jonathan, et al.
Publicado: (2022)

DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors
por: Bambury, Richard M, et al.
Publicado: (2015)

Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized Trial
por: McKay, Rana, et al.
Publicado: (2019)

Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma
por: Baras, Alexander S., et al.
Publicado: (2015)

Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma
por: Jun, Tomi, et al.
Publicado: (2022)

Emerging Therapies in Penile Cancer
por: Alencar, Antonio Machado, et al.
Publicado: (2022)

Correction: Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma
por: Baras, Alexander S., et al.
Publicado: (2015)

Gene expression in primary and metastatic kidney cancer to discover drivers of metastasis and targets for drug development
por: Zhao, Amy, et al.
Publicado: (2015)

NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
por: Gupta, Shilpa, et al.
Publicado: (2020)

FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy
por: Ning, Yang‐Min, et al.
Publicado: (2017)

A Case Report Demonstrating the Potential Clinical Benefit of Exhaustive Molecular Profiling in an Aggressive Muscle-Invasive High-Grade Metastatic Urothelial Carcinoma
por: Ramírez de Olano, Amaya, et al.
Publicado: (2017)

QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors
por: Ghatalia, P, et al.
Publicado: (2015)

Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Hong, Joohyun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_piuc5lp0scs14ut8g6gt53ba6k